Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 2/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364295 | 0.94 | BDKRB2 (0.48) | F2RBDKRB2NTSR1ITGB3ITGA2B | |
| SCHEMBL29582550 | 0.89 | BDKRB2 (0.48) | F2RNMUR2BDKRB2NTSR1F2 | |
| SCHEMBL29462901 | 0.89 | KEAP1 (0.46) | NTSR1ITGB3ITGA2BF2GRB2 | |
| SCHEMBL29364214 | 0.89 | KEAP1 (0.46) | NTSR1ITGB3ITGA2BF2GRB2 | |
| SCHEMBL29281779 | 0.88 | NMUR2 (0.45) | NMUR2NMUR1 | |
| SCHEMBL29281778 | 0.88 | NMUR2 (0.45) | NMUR2NMUR1 | |
| SCHEMBL28313317 | 0.85 | ACE (0.48) | F2RF2 | |
| SCHEMBL28313314 | 0.85 | ACE (0.48) | F2RF2 | |
| SCHEMBL30321462 | 0.84 | F2R (0.48) | F2RNMUR2NMUR1BDKRB2NTSR1 | |
| SCHEMBL29377971 | 0.84 | F2 (0.55) | BDKRB2NTSR1F2GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | claimed |
| WO-2025090926-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES WITH SURFACE-BOUND GENE EDITING TOOLS FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-05-01 | — | — | WO | claimed |
| US-20240358640-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION | 2024-10-31 | — | — | US | claimed |
| US-12064514-B2 | Ultrasound-sensitive peptide particles for spatially resolved molecule delivery | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-08-20 | — | — | US | claimed |
| US-20240238383-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIV OF LOWA RESEARCH FOUNDATION (US) | 2024-07-18 | — | — | US | claimed |
| US-20240109979-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FACELLITATE GMBH (DE) | 2024-04-04 | — | — | US | claimed |
| EP-4340894-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | University Of Iowa Research Foundation (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4301788-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2024-01-10 | — | — | EP | claimed |
| WO-2022246280-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022184899-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FACELLITATE GMBH (DE) | 2022-09-09 | — | — | WO | claimed |
| EP-4053163-A1 | CELL ATTACHMENT MATERIALS, DEVICES AND USES THEREOF | FaCellitate GmbH (DE) | 2022-09-07 | — | — | EP | claimed |
| US-20260108663-A1 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | SURMODICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12552846-B2 | Modified BCL9 mimetic peptides | Sapience Therapeutics, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| EP-3994160-A1 | MODIFIED BCL9 MIMETIC PEPTIDES | Sapience Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022026906-A9 | LYSOSOMAL TARGETING MOLECULES COMPRISING KNOTTIN PEPTIDES AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
| CN-114144424-A | Modified BCL9 mimetics | 智慧疗法有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552846-B2 | Modified BCL9 mimetic peptides | BCL9, BCL9L, BCL2L2 | F2R 1459/4885NMUR2 2158/4885NMUR1 2708/4885 |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | HDGFL3, HDGF, HM13 | F2R 2018/4885NMUR2 2244/4885NMUR1 2130/4885 |
| US-20260108663-A1 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | VCL, RAD54L, SELP | F2R 638/4885NMUR2 3516/4885NMUR1 3473/4885 |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | F2R 4090/4885NMUR2 4494/4885NMUR1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.